Form 4: AbbVie Executive Perry C. Siatis Reports Stock Transactions
SEC Form 4
EVP, GC AND SECRETARY Perry C. Siatis reports acquisition and disposal of AbbVie Inc. stock and derivative securities on February 23, 2024.
Summary
- On February 23, 2024, Perry C. Siatis, EVP, GC AND SECRETARY of AbbVie Inc., reported transactions involving AbbVie's common stock and stock options.
- Siatis acquired 2,919 shares at $144.54, 3,519 shares at $105.92, and 7,315 shares at $149.62 through option exercises.
- He also sold 13,753 shares at a weighted average price of $177.51, with individual sales ranging from $177.01 to $177.73.
- Following these transactions, Siatis directly owns 28,173 shares of AbbVie common stock.
- He also holds options to buy 2,919 shares at $144.54 and 14,629 shares at $149.62.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by an executive officer, which is common for publicly traded companies like AbbVie. It provides transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives, ensuring transparency in insider trading activities.
- Similar filings are made by executives at comparable pharmaceutical companies like Johnson & Johnson (JNJ) and Pfizer (PFE) when they engage in stock transactions.
- The details disclosed, such as the number of shares bought or sold and the prices, are consistent with the level of information required in such filings across the industry.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a key executive.
- The sale of shares could exert downward pressure on the stock price, while the acquisition of shares through option exercises could be seen as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 11/01/2023 | Reporting Person entered into a Rule 10b5-1 plan. |
| 02/17/2023 | Date exercisable for options to buy common stock. |
| 02/18/2022 | Date exercisable for options to buy common stock. |
| 02/16/2024 | Date exercisable for options to buy common stock. |
| 02/23/2024 | Date of transactions: acquisition and disposal of AbbVie stock and derivative securities. |
| 02/27/2024 | Date of report. |
| 02/16/2032 | Expiration date for options to buy common stock. |
| 02/17/2031 | Expiration date for options to buy common stock. |
| 02/15/2033 | Expiration date for options to buy common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.